靶向药物

随着当代分子生物学和细胞生物学的发展，出现了治疗癌症的分子靶向药物（targetedmedicine）。

With the development of modern molecular biology and cellular biology , targeted medicine came into being which can treat cancer .

靶向药物通过作用于靶点发挥抗肿瘤作用，有相应的优势人群。

Targeted medicine plays an important part in anti-neoplasms by target point and has advantageous group itself .

近年来国际上对其治疗的研究已主要集中在分子水平上，如抗肿瘤坏死因子（TNF）抗体，T细胞靶向药物等。

Recently some new medicines as anti-TNF bodies and T cell directed agents are used in treatment .

VEGF通路和Notch通路在肿瘤血管生成中的相互作用及靶向药物的研发

Interaction of VEGF Pathway and Notch Pathway in Tumor Angiogenesis and the Targeting Drug Development

水基稳定分散的靶向药物用纳米Fe3O4的制备

Preparation of Water-based Stabilized Dispersion of Nanon Fe_3O_4 Used in Target-orientation Drug

近年来，靶向药物治疗成为NSCLC治疗的重要手段。

Recently , the target-direct treatment has become an important stratagem in NSCLC therapy .

TACE联合分子靶向药物治疗原发性肝癌的研究进展

Combination of TACE with molecularly targeted agent in management of advanced HCC

丝/苏氨酸蛋白激酶Akt及其靶向药物研究进展

Serine / threonine protein kinase Akt and Akt targeting anticancer drug development

根据目前的研究发现，II期临床试验计划将金硫代苹果酸盐与其他参与癌症生长的分子靶向药物联用。

Based on findings to date , a phase II clinical trial is being planned to combine aurothiomalate with agents targeted at other molecules involved in cancer growth .

Baker解释到，靶向药物主要是通过特异性阻断异常细胞中的分子，而不影响正常细胞。

Targeted drugs are designed to knock out specific molecules that occur in abnormal cells , while sparing normal cells .

分子靶向药物bevacizumab是针对血管内皮生长因子（VEGF）的重组人源化单克隆抗体，在多种恶性肿瘤的治疗中显示了临床效果。

The targeted drug bevacizumab is an anti-VEGF monoclonal antibody , it has clinical effect on many malignant tumors .

制备了可用作靶向药物载体的磁性β-环糊精聚合物微球.以环氧氯丙烷为交联剂，使β-环糊精包裹在Fe3O4表面上，制得了磁性β-环糊精聚合物微球。

Magnetic β - cyclodextrin polymer microspheres are prepared by crosslinking epichlorohydrin .

消除融合基因bcr／abl是治疗CML，消除其耐药和复发的关键，而寻找高效低毒的新型靶向药物是CML治疗的重要课题之一。

Herein , it is an significant topic to search novel targeted drug for the fusion gene eliminated .

本文将对5-FU、新一代化疗药物以及分子靶向药物在转移性结肠癌治疗的演进及新进展作一综述。

In this review , we discuss the current advances in combined management of metastatic colorectal cancer of 5-Fu , chemotherapy , Molecular targeted therapy .

Pluronic嵌段共聚物胶束作为靶向药物载体

Micellae of Pluronic Triblock Copolymers as Targeting Drug Microcarriers

目的：探讨胃肠间质瘤（GIST）的CT表现及分子靶向药物甲磺酸伊马替尼（STI571）对胃肠间质瘤疗效的CT评价。

Objective : To explore CT in gastrointestinal stromal tumor ( GIST ) and evaluation the GIST treated with molecular targeted drug Imatinib mesylate ( STI 571 ) by CT .

结论研究显示，NF-κB抑制剂姜黄素可调控IBD鼠科模型中的炎症因子IL-1βmRNA和IL-10mRNA表达。姜黄素有可能是一种有潜能的IBD的靶向药物。

Conclusions Curcumin could modulate the expressions of IL-1 β and IL-10 mRNA in murine model of IBD , which suggests the potential of curcumin as a targeted therapeutic agent for IBD .

骨靶向药物四环素预防激素增强Shwartzman反应骨坏死的实验研究

Tetracycline as a bone targeted agent in prevention of steroid-enhanced osteonecrosis induced by Shwartzman reaction

这些发现给出了一种可能性，即针对CHOP基因的靶向药物能静息内质网细胞的应激性，这是治疗美国“第一杀手”心脏病的有效方法。

The finding opens the possibility that drugs targeting the CHOP gene could silence ER cell stress and be an effective way of treating heart disease , the number one killer in the US .

选择合适的靶向药物使药物选择性分布于RA炎性关节，降低或消除其对正常组织和关节的免疫抑制作用，能有效提高RA药物的治疗效果。

Select the appropriate drug design methods to make the drug selective distribution of inflammatory joints in RA , to reduce or eliminate its immunosuppressive effects on normal tissues and joints , can effectively improve the treatment of RA biotherapeutic agent .

Herceptin是美国FDA批准的第一种分子靶向药物，为乳腺癌尤其是HER2过表达乳腺癌的临床治疗带来了新的突破。

As the first molecular drug , which was approved by FDA , Herceptin bring a new break-through for breast cancer clinical treatment , especially for HER2 / neu positive breast cancer patients .

随着核磁共振及X-射线晶体衍射技术的发展，IgE-Fc和FcεRI的晶体结构逐步得到了精确解析，从而为设计靶向药物提供了重要信息。

With the development of NMR and X-ray diffraction , the crystal structure of IgE-Fc and Fc ε RI were resolve precisely , which offered significant information for designing new drugs .

而磁性材料作为一种常见的功能性材料在生物医学和生物技术方面更有着广泛的应用，如蛋白质和酶的固定化、免疫测定、RNA和DNA的提纯、细胞分离及磁性靶向药物。

Among that , magnetic materials as a common functional materials is more in a wide range of applications in biomedical and biotechnology , such as enzyme immobilization , protein and immune determination , the purification of RNA and DNA , cell separation and magnetic targeted drugs [ 6-9 ] .

以表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）为基础的分子靶向药物治疗在肺癌的治疗中发挥着重要作用，成为国内外研究的热点。

The epidermal growth factor receptor kinase inhibitors ( EGFR-TKI ) play an important role in molecular target therapy of lung cancer .

分子靶向药物伊马替尼能够与Bcr-Abl激酶结合而成功治疗慢性粒细胞性白血病，然而该激酶的点突变常导致伊马替尼耐药，使治疗失败。

Molecularly targeted agent imatinib can successfully control chronic myelogenous leukemia by combining to Bcr-Abl kinase . But the mutations of Bcr-Abl kinase often result in resistance to imatinib and cause failure of treatment .

BTZ是一种很有前景的治疗T细胞淋巴瘤的靶向药物，为BTZ与THP联合治疗T细胞淋巴瘤的临床研究提供了实验依据。

Our study demonstrated that BTZ plus THP presents a synergistically antitumor effect on T cell lymphoma cells and may be an optimal regimen in clinical trial of T cell lymphoma .

本论文重组ApoAⅠ成功的分泌表达且表达水平明显高于其它表达系统，再次显示了P.pastoris表达系统的优势，也为ApoAⅠ作为肝脏靶向药物的研究、制备和应用奠定了基础。

The success of high expression of ApoA ⅰ shows the superiority of P.pastoris and will meet its large research , production and Application for the target-drug of liver .

因此，PI3K抑制剂在抑制肿瘤细胞增殖、诱导肿瘤细胞凋亡和逆转肿瘤细胞耐药性等方面具有独特的优势，可以单独用药或与其它靶向药物联合用药。

Therefore , PI3K inhibitors have unique advantages in inhibiting cancer cell proliferation , inducing apoptosis and reversing cancer drug resistance , and they can be used as a single agent or in combination with other molecule targeted drugs .

背景与目的：Herceptin是目前治疗Her2/neu高表达晚期转移性乳腺癌的常用分子靶向药物。

Background and Purpose : Herceptin could be a potential candidate for targeted therapy in Her2 / neu overexpression metastatic breast cancer , but its efficacy has proven to be limited when used as a single agent .

在药物浓度为10mg/mL，pH值为6的60℃药液中，提纯凹凸棒石及其磁性靶向药物载体对氟尿嘧啶的吸附量分别为26.3mg/g和27.2mg/g。

When the drug concentration is 10mg / mL and pH value is 6 , the capacity for absorption of fluorouracil by the purified attapulgite and the magnetic targeting drug carrier is 26.3 mg / g and 27.2mg/g at 60 ℃, respectively .